564 related articles for article (PubMed ID: 29164723)
1. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
[No Abstract] [Full Text] [Related]
4. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
[TBL] [Abstract][Full Text] [Related]
5. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
6. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
MacGlashan D; Saini S; Schroeder JT
J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab may not inhibit mast cell and basophil activation in vitro.
Gericke J; Ohanyan T; Church MK; Maurer M; Metz M
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1832-6. PubMed ID: 25257818
[TBL] [Abstract][Full Text] [Related]
8. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
Lin H; Boesel KM; Griffith DT; Prussin C; Foster B; Romero FA; Townley R; Casale TB
J Allergy Clin Immunol; 2004 Feb; 113(2):297-302. PubMed ID: 14767445
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic autoimmune urticaria with omalizumab.
Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
[TBL] [Abstract][Full Text] [Related]
12. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
13. Comparable actions of omalizumab on mast cells and basophils.
Serrano-Candelas E; Martinez-Aranguren R; Valero A; Bartra J; Gastaminza G; Goikoetxea MJ; Martín M; Ferrer M
Clin Exp Allergy; 2016 Jan; 46(1):92-102. PubMed ID: 26509363
[TBL] [Abstract][Full Text] [Related]
14. Current Strategies to Inhibit High Affinity FcεRI-Mediated Signaling for the Treatment of Allergic Disease.
Gomez G
Front Immunol; 2019; 10():175. PubMed ID: 30792720
[TBL] [Abstract][Full Text] [Related]
15. Effects of omalizumab on basophils: Potential biomarkers in asthma and chronic spontaneous urticaria.
Poddighe D; Vangelista L
Cell Immunol; 2020 Dec; 358():104215. PubMed ID: 33137647
[TBL] [Abstract][Full Text] [Related]
16. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
[No Abstract] [Full Text] [Related]
17. Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.
Alizadeh Aghdam M; Knol EF; van den Elzen M; den Hartog Jager C; van Os-Medendorp H; Knulst AC; Otten HG; Röckmann H
Clin Exp Allergy; 2020 Mar; 50(3):364-371. PubMed ID: 31925825
[TBL] [Abstract][Full Text] [Related]
18. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria.
Rauber MM; Pickert J; Holiangu L; Möbs C; Pfützner W
Allergy; 2017 Dec; 72(12):1904-1911. PubMed ID: 28585360
[TBL] [Abstract][Full Text] [Related]
19. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.
Chang TW; Chen C; Lin CJ; Metz M; Church MK; Maurer M
J Allergy Clin Immunol; 2015 Feb; 135(2):337-42. PubMed ID: 24948369
[TBL] [Abstract][Full Text] [Related]
20. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.
Eckman JA; Sterba PM; Kelly D; Alexander V; Liu MC; Bochner BS; Macglashan DW; Saini SS
J Allergy Clin Immunol; 2010 Apr; 125(4):889-895.e7. PubMed ID: 19962744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
